Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning

Authors:  Stephanie N. Dorman^a, Katherina Baranova^a, Joan H.M. Knoll^b,c,d, Brad L. Urquhart^e, Gabriella Mariani^f, Maria Luisa Carcangiu^f, Peter K. Rogan^a,d,g,h*

^aDepartment of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, ^bDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, ^cMolecular Diagnostics Division, Laboratory Medicine Program, London Health Sciences Centre, ON, Canada, ^dCytognomix Inc., London ON, Canada, ^eDepartment of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, ^fDepartment of Diagnostic and Laboratory Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, ^gDepartment of Computer Science, University of Western Ontario, London, ON, Canada, ^hDepartment of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada

will be published in a forthcoming issue of the journal “Molecular Oncology”.

We presented:

“Discovery of Primary, Cofactor, and Novel Transcription Factor Binding Site Motifs by Recursive, Thresholded Entropy Minimization”

by Ruipeng Lu, Eliseos Mucaki, and Peter Rogan

at the Regulatory Genomics Special Interest Group meeting in Dublin, Ireland:     Link to abstract

Khan WA, Rogan PK, Knoll JH. Reversing chromatin accessibility differences that distinguish homologous mitotic metaphase chromosomes. Molecular Cytogenetics, in press.

Stay tuned for posts providing details and links to the manuscript once it is available online at the journal website.

FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity, and is a familial breast cancer risk factor.
Peterlongo et al. Hum Mol Genet. 2015 Jun 30. pii: ddv251.